ImmPACT Bio Announces FDA Clearance of IND Application
Dual CD19 and CD20-targeting CAR T therapy offers broad immune targeting and potential to reset immune system No neurotoxicity and only Grade 1 cytokine release syndrome in ongoing UCLA investigator-led study in lymphoma West Hills, Calif., August 15, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) […]
